MedTrace Logo

Hemodynamic Monitoring in Liver Transplant With VEnaRt Cardiac Output Versus Swan-Ganz Catheter (VERO Study)

NCT04825015 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2023-08-25

No results posted yet for this study

Summary

The Swan-Ganz catheter is the gold standard to measure cardiac output during liver transplantation surgery. This is an invasive hemodynamic monitoring system.

The VenArt Cardiac Output (Mespere LifeSciences, Waterloo, Canada) is a new, innovative and non-invasive device that permits hemodynamic monitoring.

With a software based on Fick's principle it is able to calculate cardiac output, cardiac index and continuous cardiac output.

The hypothesis of this study is to investigate the precision and accuracy of this method versus the standard of care during liver transplantation.

Conditions

  • Cardiac Output, Low
  • Liver Transplant; Complications

Interventions

DEVICE

VEnaRt Cardiac Output

Every patient is monitored during liver transplantation with VEnaRt Cardiac Output versus Swan-Ganz Catheter

Sponsors & Collaborators

  • Azienda Sanitaria-Universitaria Integrata di Udine

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2022-12-15
Completion
2022-12-15
FDA Device
Yes

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04825015 on ClinicalTrials.gov